ZEO SCIENTIFIX, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.01 USD | -15.83% |
|
-22.31% | -0.98% |
| 18/03 | Zeo ScientifiX, Inc. Reports Earnings Results for the First Quarter Ended January 31, 2024 | CI |
| 05/03 | Zeo ScientifiX, Inc. has Changed its Ticker to ZEOX from OCEL | CI |
| Sales 2022 | 6.49M 542M | Sales 2023 | 4.56M 380M | Capitalization | 12.89M 1.08B |
|---|---|---|---|---|---|
| Net income 2022 | -8M -667M | Net income 2023 | -6M -501M | EV / Sales 2022 | 5.78 x |
| Net cash position 2022 | 2.71M 227M | Net cash position 2023 | 1.06M 88.7M | EV / Sales 2023 | 2.59 x |
| P/E ratio 2022 |
-3.48
x | P/E ratio 2023 |
-1.78
x | Employees | 23 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 59.49% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -15.83% | ||
| 1 week | -22.31% | ||
| Current month | -19.20% | ||
| 1 month | -42.29% | ||
| 3 months | -25.19% | ||
| 6 months | -43.89% | ||
| Current year | -0.98% |
1 week
1.01
1.30
1 month
1.012.00
Current year
1.013.54
1 year
0.904.80
3 years
0.9077.80
5 years
0.90125.98
10 years
0.70300.00
| Managers | Title | Age | Since |
|---|---|---|---|
Harry Leider
CEO | Chief Executive Officer | 66 | 06/23/06 |
Ian Bothwell
DFI | Director of Finance/CFO | 63 | 04/16/04 |
Howard Golub
CTO | Chief Tech/Sci/R&D Officer | 71 | 06/23/06 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ian Bothwell
DFI | Director of Finance/CFO | 63 | 04/16/04 |
Steven Glauser
BRD | Director/Board Member | 76 | 23/22/23 |
| Director/Board Member | 62 | 19/22/19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 03/24/03 | 1.01 | -15.83% | 592 |
| 02/24/02 | 1.2 | -4.00% | 13,599 |
| 01/24/01 | 1.25 | 0.00% | 2,029 |
| 29/24/29 | 1.25 | -3.85% | 3,202 |
| 26/24/26 | 1.3 | +4.00% | 5,944 |
Delayed Quote OTC Markets, May 03, 2024 at 10:04 pm IST
More quotes
Zeo ScientifiX, Inc. is a clinical-stage biopharmaceutical company. It develops biological therapeutics for the treatment of degenerative diseases and regenerative medicine. Its products are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent and an autologous non-manipulated biologic containing the nanoparticle fraction from a patientâs own peripheral blood (RAAM Products). Its RAAM Products and related services are principally used in the health care industry, administered by doctors and clinics. The Companyâs product, Zofin (Organicell Flow), is an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs. Patient Pure X, its autologous product, is a non-manipulated biologic containing the nanoparticle fraction from a patientâs own peripheral blood.
Sector
Pharmaceuticals
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -0.98% | 6.19M | |
| +14.23% | 69.5B | |
| +7.11% | 8.2B | |
| -20.55% | 7.97B | |
| -4.06% | 7.84B | |
| +2.26% | 4.66B | |
| +17.12% | 4.32B | |
| +1.41% | 4.19B | |
| -3.02% | 3.89B | |
| +21.42% | 3.62B |
- Stock Market
- Equities
- ZEOX Stock
